<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878408</url>
  </required_header>
  <id_info>
    <org_study_id>I-Give</org_study_id>
    <secondary_id>IDRCB : 2013-A01639-36</secondary_id>
    <nct_id>NCT02878408</nct_id>
  </id_info>
  <brief_title>Immuno-Genetic, Inflammation, Retro-Virus, Environment</brief_title>
  <acronym>I-Give</acronym>
  <official_title>Immuno-Génétique, Inflammation, Retro-Virus, Environnement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pr. Marion Leboyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Agency, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation FondaMental</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunology combined to neurobiology now offer prominent tools to yield biomarkers, so far&#xD;
      missing in psychiatry, and to design innovative treatment approaches based on the discovery&#xD;
      of new molecular and cellular targets. As Bipolar Disorder and Schizophrenia are now known to&#xD;
      be significantly associated with neuro-inflammation, the project I-GIVE will combine&#xD;
      multidisciplinary approaches (clinical, viral, immunological, genetic) to explore a global&#xD;
      hypothesis placing the Human Endogenous Retro-Virus, HERV-W, at the crossroads between&#xD;
      susceptibility to environmental factors (such as winter-spring births, infections,&#xD;
      urbanicity…) and genetic factors controlling immune responses.&#xD;
&#xD;
      Thus I-GIVE will allow identification of new biomarkers and their correlation with clinical&#xD;
      profiles and immuno-inflammatory/immuno-genetic markers, and description of&#xD;
      patho-physiological mechanisms of a psychiatric disorder. In addition, I-GIVE should help to&#xD;
      design innovative treatments and foster personalized psychiatry tailored to the needs of each&#xD;
      patient. Notably, monoclonal antibodies anti-HERV-W Env will be assessed in a preclinical&#xD;
      model for their ability to slow, stop, or even reverse the progression of the psychosis in&#xD;
      patients. I-GIVE project should thus lead to major results that will have strong impacts on&#xD;
      the scientific community, pharmaceutical industries and, in a longer term, on improvement of&#xD;
      patients suffering Bipolar Disorder or Schizophrenia and their family.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators and others have been able to demonstrate that HERV-W envelope gene (Env)&#xD;
      encodes a pro-inflammatory and neurotoxic protein after reactivation by environmental&#xD;
      factors. In this context, the investigators have reported preliminary data showing an&#xD;
      association between Human Endogenous Retroviruses type &quot;W&quot; family (HERV-W) and major&#xD;
      psychotic disorder, bipolar disorder (BD) and schizophrenia (SZ) : In 2008, the investigators&#xD;
      reported for the first time, the presence of ENV protein in the serum of 50 % of SZ patients&#xD;
      associated with a chronic inflammatory status reflected by elevated serum level of C-Reactive&#xD;
      Protein (CRP). The investigators have been able to confirm this finding and extend it to BD&#xD;
      and showed an elevation of HERV-W RNA transcripts both in BD and SZ as compared to healthy&#xD;
      controls. Furthermore, the investigators also observed for the first time that toxoplasma&#xD;
      Gondii, known to be able to induce reactivation of HERV-W, is associated with an increased&#xD;
      risk to develop BD (OR: 2.3) close to the one previously observed in SZ (OR= 2.17)&#xD;
&#xD;
      The present project I-GIVE aims to extend and refine such findings and to obtain a proof of&#xD;
      concept of the involvement of Human Endogenous Retrovirus elements in bipolar disorder and&#xD;
      schizophrenia. I-GIVE is divided into four complementary scientific tasks:&#xD;
&#xD;
        1. assessing the systemic HERV-W (ENV and GAG) antigen serum levels and the RNA and DNA&#xD;
           copy number variants of stabilized and acutely ill patients,&#xD;
&#xD;
        2. measuring the systemic associated immuno-inflammatory cascade in BD patients at&#xD;
           different stages of the disorder and occurrence of medical comorbidities,&#xD;
&#xD;
        3. identifying the clinical characteristics of patients according to HERV-W expression and&#xD;
           immuno-inflammatory profiles,&#xD;
&#xD;
        4. exploring the gene (immuno-genetic) x environment interactions that may modulate the&#xD;
           immuno-inflammatory response&#xD;
&#xD;
      Clinical and biological data from acute BP and SZ patients will be compared first with&#xD;
      themselves at two different times. They will be compared also to healthy control's data, and&#xD;
      third to stabilised BP and SZ patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HERV-W</measure>
    <time_frame>inclusion</time_frame>
    <description>measure of HERV retroviral DNA, RNA and envelop proteins</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>acute Bipolar disorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acute Schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stable Bipolar disorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sampling and data collection (only one visit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stable Schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sampling and data collection (only one visit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood sampling and data collection (only one visit)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors</description>
    <arm_group_label>acute Bipolar disorder</arm_group_label>
    <arm_group_label>acute Schizophrenia</arm_group_label>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_label>stable Bipolar disorder</arm_group_label>
    <arm_group_label>stable Schizophrenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bipolar disorder or Schizophrenia (according to Diagnostic and Statistical Manual of&#xD;
             Mental Disorders IV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  Vaccination within 4 precedent weeks&#xD;
&#xD;
          -  Severe neurologic illness&#xD;
&#xD;
          -  Immunosuppressing or immuno-modulating treatment.&#xD;
&#xD;
          -  Infectious disease within 4 precedent weeks (including HIV 1 et 2, Hepatite B, C)&#xD;
&#xD;
          -  Refuse to have HIV and hepatite B et C tests or to be informed of their results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Leboyer, Pr</last_name>
    <phone>(33) 1 49 81 38 22</phone>
    <email>marion.leboyer@fondation-fondamental.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Romain Richard</last_name>
    <email>jean-romain.richard@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatry Department of Perrens Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Investigations Center of Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatry Department of Mondor Hospital</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatry Department of Widal Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EPS Maison Blanche</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatry Department of R. Dubos Hospital</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fondation-fondamental.org/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fondation FondaMental</investigator_affiliation>
    <investigator_full_name>Pr. Marion Leboyer</investigator_full_name>
    <investigator_title>Responsible for Pôle de psychiatrie of Hospital Albert Chenevier- Henri Mondor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

